Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H19ClF3NO5 |
Molecular Weight | 469.838 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CC[C@H]([C@@H]1CO)C2=C3OC(=CC(=O)C3=C(O)C=C2O)C4=CC=C(C=C4Cl)C(F)(F)F
InChI
InChIKey=MRPGRAKIAJJGMM-OCCSQVGLSA-N
InChI=1S/C22H19ClF3NO5/c1-27-5-4-12(14(27)9-28)19-15(29)7-16(30)20-17(31)8-18(32-21(19)20)11-3-2-10(6-13(11)23)22(24,25)26/h2-3,6-8,12,14,28-30H,4-5,9H2,1H3/t12-,14+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/26810603Curator's Comment: Description was created based on several sources, including
http://www.chemietek.com/voruciclib-details.aspx
http://www.pharmacodia.com/yaodu/html/v1/chemicals/95276ef6535840ec6e432a7fc28688cb.html
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26810603
Curator's Comment: Description was created based on several sources, including
http://www.chemietek.com/voruciclib-details.aspx
http://www.pharmacodia.com/yaodu/html/v1/chemicals/95276ef6535840ec6e432a7fc28688cb.html
Voruciclib (also known as P1446A-05) is a flavone-based, potent and selective CDK 4/6 inhibitor with activity in multiple BRAF-mutant and wild type cell lines. It is currently in clinical trials in combination with BRAF inhibitor (PLX4032) to treat advanced BRAF-mutant melanoma. Voruciclib has significant inhibitory activity against cutaneous and uveal melanoma. Mechanistic studies revealed that P1446A-05 inhibits phosphorylation targets of CDK members, and induces cell cycle arrest and apoptosis irrespective of melanoma genotype or phenotype. Voruciclib Hydrochloride is in phase I clinical trials by Piramal Life Sciences for the treatment of chronic lymphocytic leukaemia and malignant melanoma.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3116 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26810603 |
|||
Target ID: CHEMBL331 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26810603 |
|||
Target ID: CHEMBL2508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26810603 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. | 2015 |
|
A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. | 2016 Jul 2 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00840190
In Subjects With Advanced Refractory Malignancies:
Voruciclib available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of Voruciclib. Four such cycles will be administered.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26810603
Treatment of A375 (BRAFV600E/NRASWT), SK-MEL-63 (NRASQ61K/BRAFWT), and OCM-1 (uveal) revealed increases
in both sub-G1 fractionation and G2/M arrest at 5 uM Voruciclib; both changes were statistically significant compared to DMSO-treated controls. At lower Voruciclib concentrations (e.g. 0.5 uM), there appeared to be an increase in the G1 population.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2185
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL3545218
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY | |||
|
100000181775
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY | |||
|
67409219
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY | |||
|
9791
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY | |||
|
1000023-04-0
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY | |||
|
C141430
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY | |||
|
DB15157
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY | |||
|
W66XP666AM
Created by
admin on Sat Dec 16 08:00:33 GMT 2023 , Edited by admin on Sat Dec 16 08:00:33 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SALT/SOLVATE (PARENT)